YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
This article first appeared on GuruFocus. An In-Depth Look at the Upcoming Payout and Long-Term Dividend Sustainability Hansoh Pharmaceutical Group Co Ltd (HNSPF) recently announced a total dividend of $0.04 per share, with the ex-dividend…
Chinese corporate earnings are on a tear, giving investors clues on which stock sectors offer untapped returns, according to Goldman Sachs. Nearly half of MSCI China index constituents beat estimates in the second quarter, with IT and heal…
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[GSK -Glaxosmithkline headquarters office building in Poznan.] Magdalena Wygralak GSK (GSK [https://seekingalpha.com/symbol/GSK]) announced on Friday a Phase 3 trial win in China for risvutatug rezetecan (Ris-Rez), an antibody-drug conjuga…
GSK plc GSK announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to risvutatug rezetecan, its investigational B7-H3-targeted antibody-drug conjugate (“ADC”), for the treatment of small-cel…
International companies find a new, frictionless path to secure regional approvals in Veristat SOUTHBOROUGH, Mass., March 11, 2026--(BUSINESS WIRE)--Veristat, a global clinical research organization (CRO) and consultancy specializing in co…
Regeneron Pharmaceuticals, Inc. Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEW…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Terns Pharmaceuticals (TERN) is back in focus after amending its ag…
Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $…
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is included in our list of the 11 Best Performing Stocks in the Last 12 Months.Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment On January 16, 2026, Terns Phar…
Hansoh Pharmaceutical Group (SEHK:3692) has been catching the eye of investors lately, not for a flashy headline event, but simply for its stock’s consistent movement over recent months. Sometimes, it is the quieter stretches in the market…
China's healthcare sector is on track to secure record fundraising this year, driven by robust global investor demand and growth momentum, according to analysts. Several Chinese biopharmaceutical companies have tapped equity capital market…
Investing.com -- Bank of America (BofA) on Thursday highlighted global stocks that rank highest across earnings, price, and news momentum, based on its Triple Momentum Allocator. According to the report, stocks with strong triple momentum…
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and reduced its price objective from…
Partnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater China SCYNEXIS will receive a $10 million upfront payment and will also be eligible…
Partnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater China SCYNEXIS will receive a $10 million upfront payment and will also be eligible…